| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Irbesartan D4 targets the angiotensin II type 1 (AT1) receptor, a G protein-coupled receptor that mediates the vasoconstrictor and aldosterone-releasing effects of angiotensin II. By blocking AT1 receptor activation, Irbesartan inhibits angiotensin II-induced vasoconstriction, reduces peripheral vascular resistance, and lowers blood pressure. The compound also increases the supply of blood and oxygen to the heart. The deuterated D4 form is used as an analytical internal standard for quantifying Irbesartan in biological matrices and does not alter the receptor binding or pharmacological activity compared to the parent compound.
|
|---|---|
| ln Vitro |
In vitro, Irbesartan (parent compound) acts as a selective and potent AT1 receptor antagonist. The compound binds to the AT1 receptor with high affinity, competitively blocking the binding of angiotensin II and inhibiting receptor-mediated signaling pathways including G protein activation, phospholipase C activation, calcium mobilization, and MAPK/ERK signaling. In cellular assays, Irbesartan inhibits angiotensin II-induced smooth muscle contraction, aldosterone secretion, and cell proliferation. The D4-labeled form is expected to exhibit identical in vitro receptor binding and activity to the parent compound, making it suitable as an internal standard for quantification.
|
| ln Vivo |
In vivo, Irbesartan is clinically used for the management of hypertension and the treatment of diabetic nephropathy. The compound is orally bioavailable and has a long duration of action, allowing once-daily dosing. Irbesartan effectively lowers blood pressure in stroke-prone spontaneously hypertensive rats and in patients with hypertension. The compound also provides renoprotective effects in patients with type 2 diabetes and hypertension. The D4-labeled form is used as an internal standard for pharmacokinetic studies and therapeutic drug monitoring, enabling accurate quantification of Irbesartan levels in plasma and tissue samples by GC- or LC-MS.
|
| Enzyme Assay |
In vitro receptor binding assays for Irbesartan are performed using membrane preparations from cells expressing recombinant human AT1 receptors. Radiolabeled ligands such as [¹2⁵I]-Sar¹-Ile⁸-angiotensin II are used. Membranes are incubated with varying concentrations of Irbesartan or the D4 internal standard in assay buffer at room temperature for 60-90 minutes. Bound and free radioligands are separated by rapid filtration through glass fiber filters. Filter-bound radioactivity is quantified by gamma counting. Ki values are calculated using the Cheng-Prusoff equation. Functional assays measure angiotensin II-stimulated calcium mobilization or inositol phosphate accumulation in cells expressing AT1 receptors to confirm antagonist activity.
|
| Cell Assay |
Cellular assays for Irbesartan are performed using cell lines expressing AT1 receptors, such as vascular smooth muscle cells or HEK-293 cells transfected with AT1 receptors. Cells are cultured in appropriate medium and seeded in 96-well plates. Cells are treated with serial dilutions of Irbesartan (0.001-10 microM) for 30-60 minutes prior to stimulation with angiotensin II (10-100 nM). Calcium mobilization is measured using fluorescent calcium indicators (e.g., Fluo-4). Cell proliferation is assessed by [3H]-thymidine incorporation. IC₅0 values for inhibition of angiotensin II-stimulated responses are calculated from dose-response curves. The D4 internal standard is used in LC-MS/MS quantification of Irbesartan in cell lysates.
|
| Animal Protocol |
In vivo animal studies for Irbesartan are conducted in rodent models of hypertension and diabetic nephropathy. Spontaneously hypertensive rats (SHR) or angiotensin II-infused mice are administered Irbesartan orally at doses of 1-50 mg/kg once daily for 4-8 weeks. Blood pressure is measured by tail-cuff plethysmography or telemetry. Renal function is assessed by measuring urinary albumin excretion, creatinine clearance, and glomerular filtration rate. Histological analysis of kidney tissues is performed to assess glomerulosclerosis and tubular damage. Pharmacokinetic parameters are determined from plasma samples using LC-MS/MS with the D4 internal standard.
|
| ADME/Pharmacokinetics |
Irbesartan D4 (CAS#: 1216883-23-6) has molecular formula C2₅H2₈N₆O and molecular weight 432.55 (with four deuterium atoms). The chemical name is 2-butyl-3-{[2'-(2H-1,2,3,4-tetrazol-5-yl)(2,3,5,6-2H4)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one. The compound is an isotopically labeled internal standard for Irbesartan, an angiotensin II type 1 (AT1) receptor blocker used for hypertension and diabetic nephropathy. Purity is typically ≥95%. Storage should be at -20degC, protected from light and moisture.
|
| Additional Infomation |
Irbesartan D4 (CAS#: 1216883-23-6) is a deuterium-labeled internal standard for Irbesartan (Avapro, SR-47436), an orally active angiotensin II type 1 (AT1) receptor blocker (ARB). Irbesartan is used clinically to manage hypertension, treat diabetic nephropathy, and reduce cardiovascular risk. By blocking AT1 receptors, Irbesartan inhibits angiotensin II-induced vasoconstriction, lowers blood pressure, and provides renoprotective effects. The D4-labeled form is used in GC- or LC-MS bioanalytical methods for therapeutic drug monitoring, pharmacokinetic studies, and quality control applications. For research use only, not for human therapeutic applications.
|
| Molecular Formula |
C₂₅H₂₄D₄N₆O
|
|---|---|
| Molecular Weight |
432.55
|
| Exact Mass |
432.258
|
| CAS # |
1216883-23-6
|
| Related CAS # |
Irbesartan;138402-11-6
|
| PubChem CID |
45358998
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.15
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
682
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1=C(C(=C(C(=C1CN2C(=NC3(C2=O)CCCC3)CCCC)[2H])[2H])C4=CC=CC=C4C5=NNN=N5)[2H]
|
| InChi Key |
YOSHYTLCDANDAN-WQKXEYJYSA-N
|
| InChi Code |
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)/i11D,12D,13D,14D
|
| Chemical Name |
2-butyl-3-[[2,3,5,6-tetradeuterio-4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
|
| Synonyms |
SR-47436 D4SR47436 D4 BMS186295 D4 BMS-186295 D4
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3119 mL | 11.5594 mL | 23.1187 mL | |
| 5 mM | 0.4624 mL | 2.3119 mL | 4.6237 mL | |
| 10 mM | 0.2312 mL | 1.1559 mL | 2.3119 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
